| Literature DB >> 23844025 |
Yasmin Ahmad1, Narendra K Sharma, Iti Garg, Mohammad Faiz Ahmad, Manish Sharma, Kalpana Bhargava.
Abstract
Adaptation to hypobaric hypoxia is required by animals and human in several physiological and pathological situations. Hypobaric hypoxia is a pathophysiological condition triggering redox status disturbances of cell organization leading, via oxidative stress, to proteins, lipids, and DNA damage. Identifying the molecular variables playing key roles in this process would be of paramount importance to shed light on the mechanisms known to counteract the negative effects of oxygen lack. To obtain a molecular signature, changes in the plasma proteome were studied by using proteomic approach. To enrich the low-abundance proteins in human plasma, two highly abundant proteins, albumin and IgG, were first removed. By comparing the plasma proteins of high altitude natives with those of a normal control group, several proteins with a significant alteration were found. The up-regulated proteins were identified as vitamin D-binding protein, hemopexin, alpha-1-antitrypsin, haptoglobin β-chain, apolipoprotein A1, transthyretin and hemoglobin beta chain. The down-regulated proteins were transferrin, complement C3, serum amyloid, complement component 4A and plasma retinol binding protein. Among these proteins, the alterations of transthyretin and transferrin were further confirmed by ELISA and Western blotting analysis. Since all the up- and down- regulated proteins identified above are well-known inflammation inhibitors and play a positive anti-inflammatory role, these results show that there is some adaptive mechanism that sustains the inflammation balance in high altitude natives exposed to hypobaric hypoxia.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23844025 PMCID: PMC3699623 DOI: 10.1371/journal.pone.0067548
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Representative SDS-PAGE image of depleted human plasma sample from control and high altitude native (HAN).
Lane 1 and 3 represent crude plasma samples of control and HAN, respectively. Lane 2 and 4 represent depleted plasma samples of control and HAN, respectively. Lane M represents molecular weight marker.
Figure 2Representative gel image of plasma proteins from HAN.
The proteins were resolved according to their isoelectric point (pI) in the first (5–8 pH) and their Mw on 12% SDS-PAGE followed by silver staining. Numbers mark protein spots were differentially expressed.
List of differentially expressed plasma proteins in high altitude natives, identified by MALDI-TOF/TOF.
| Spot ID | Mascot Score | SwissProt Accession No. | Protein Name | Gene Name | Theoretical pI/mass.kDa | Observed pI/mass.kDa | % Coverage | Peptide Match | SignificantFold Change | Protein Function |
| 1 | 62 | P02774 | Vitamin D –binding protein precursor | GC | 5.65/55 | 5.3/54.49 | 22 | 5 | 1.78b | In plasma, it carries the vitamin D sterols and prevents polymerization of actin by binding its monomers. |
| 2 | 62 | P02774 | Vitamin D –binding protein precursor | GC | 5.65/55 | 5.3/54.49 | 22 | 5 | 1.57a | As described earlier |
| 3 | 62 | P02774 | Vitamin D –binding protein precursor | GC | 5.65/55 | 5.3/54.49 | 22 | 5 | 1.62a | As described earlier |
| 4 | 101 | P02790 | Hemopexin | HPX | 5.59/72 | 6.5/52.38 | 24 | 8 | 1.92c | Binds heme and transports it to the liver for breakdown and iron recovery, after which the free hemopexin returns to the circulation. |
| 5 | 93 | P02790 | Hemopexin | HPX | 5.59/72 | 6.5/52.38 | 24 | 8 | 1.68b | As described earlier |
| 6 | 93 | P02790 | Hemopexin | HPX | 5.59/72 | 6.5/52.38 | 26 | 9 | 1.86c | As described earlier |
| 7 | 93 | P02790 | Hemopexin | HPX | 5.59/72 | 6.5/52.38 | 26 | 9 | 2.12c | As described earlier |
| 8 | 144 | P02787 | Transferrin | TF | 6.64/76 | 6.8/79.28 | 31 | 17 | −1.93c | Cellular iron ion homeostasis |
| 9 | 103 | P02787 | Transferrin | TF | 6.64/76 | 6.8/79.28 | 15 | 8 | −1.95c | As described earlier |
| 10 | 103 | P02787 | Transferrin | TF | 6.64/76 | 6.8/79.28 | 15 | 8 | −1.61a | As described earlier |
| 11 | 52 | P01024 | Complement C3 | C3 | 6/184 | 6.98/70 | 8 | 2 | −3.54c | Mediator of local inflammatory process |
| 12 | 117 | P01009 | Alpha-1-antitrypsin | SERPINA1 | 4.95/55 | 5.3/46.87 | 3 | 1 | 1.83c | Inhibitor of serine proteases, Acute phase response |
| 13 | 59 | P00738 | Haptoglobin β chain | HP | 6.10/39 | 6.1/45.86 | 24 | 11 | 1.64b | It combines with free plasma Hb, preventing loss of iron through the kidneys and protecting the kidneys from damage by hemoglobin, while making the hemoglobin accessible to degradative enzymes |
| 14 | 59 | P00738 | Haptoglobin β chain | HP | 6.10/39 | 6.1/45.86 | 24 | 11 | 1.53a | As described earlier |
| 15 | 59 | P00738 | Haptoglobin β chain | HP | 6.10/39 | 6.1/45.86 | 24 | 11 | 1.58a | As described earlier |
| 16 | 59 | P00738 | Haptoglobin β chain | HP | 6.10/39 | 6.1/45.86 | 24 | 11 | 1.62a | As described earlier |
| 17 | 60 | P02743 | Serum Amyloid P | APCS | 6.12/24 | 5.5/26.28 | 15 | 2 | −1.54a | It Can interact with DNA and histones and may scavenge nuclear material released from damaged circulating cells |
| 18 | 90 | P0C0L4 | Compliment C 4A | C4A | 6.99/193 | 6.3/30.22 | 25 | 10 | −1.83 c | C4 plays a central role in the activation of the classical pathway of the complement system and inflammatory response |
| 19 | 80 | P02647 | Apolipoprotein A1 | APOA1 | 5.52/30 | 5.5/30.75 | 40 | 12 | 1.92c | Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility |
| 20 | 80 | P02647 | Apolipoprotein A1 | APOA1 | 5.52/30 | 5.5/30.75 | 40 | 12 | 1.55a | As described earlier |
| 21 | 172 | P02647 | Apolipoprotein A1 | APOA1 | 5.52/30 | 5.5/30.75 | 59 | 20 | 1.8c | As described earlier |
| 22 | 77 | P00738 | Haptoglobin α2 chain | HP | 6.10/39 | 6.1/45.86 | 22 | 10 | 1.51a | As described earlier |
| 23 | 94 | P00738 | Haptoglobin α2 chain | HP | 6.10/39 | 6.1/45.86 | 22 | 10 | 1.64a | As described earlier |
| 24 | 97 | P00738 | Haptoglobin α2 chain | HP | 6.10/39 | 6.1/45.86 | 22 | 11 | 1.69b | As described earlier |
| 25 | 47 | P02766 | Transthyretin | TTR | 5.77/15 | 5.26/15.59 | 20 | 1 | 1.8 c | Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain |
| 26 | 97 | P00738 | Haptoglobin α2 chain | HP | 6.10/39 | 6.1/45.86 | 22 | 11 | 1.75 c | As described earlier |
| 27 | 434 | P68871 | Hemoglobin beta chain | HBB | 16/7.88 | 7.8/12 | 64 | 10 | 2.21 c | Involved in oxygen transport from the lung to the various peripheral tissues.LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure |
| 28 | 117 | P01009 | Alpha-1-antitrypsin | SERPINA1 | 4.95/55 | 5.3/46.87 | 3 | 1 | 1.79b | As described earlier |
| 29 | 62 | P02774 | Vitamin D –binding protein precursor | GC | 5.65/55 | 5.3/54.49 | 22 | 5 | 1.63a | As described earlier |
| 30 | 62 | P02774 | Vitamin D –binding protein precursor | GC | 5.65/55 | 5.3/54.49 | 22 | 5 | 1.51a | As described earlier |
| 31 | 80 | P02647 | Apolipoprotein A1 | APOA1 | 5.52/30 | 5.5/30.75 | 40 | 12 | 1.57a | As described earlier |
| 32 | 80 | P02647 | Apolipoprotein A1 | APOA1 | 5.52/30 | 5.5/30.75 | 40 | 12 | 1.57a | As described earlier |
| 33 | 172 | P02647 | Apolipoprotein A1 | APOA1 | 5.52/30 | 5.5/30.75 | 59 | 20 | 1.61a | As described earlier |
| 34 | 59 | P00738 | Haptoglobin β chain | HP | 6.10/39 | 6.1/45.86 | 24 | 11 | 1.55a | As described earlier |
| 35 | 61 | P02753 | Plasma retinol binding protein | RBP4 | 5.27/18 | 5.5/23.19 | 61 | 7 | −1.87c | Delivers retinol from the liver stores to the peripheral tissues. In plasma, the RBP-retinol complex interacts with transthyretin, this prevents its loss by filtration through the kidney glomeruli. |
‘a’ denotes p<0.05. ‘b’ denotes p<0.01 and ‘c’ denotes p<0.001.
Figure 3Gene ontology annotations of the proteins identified by MALDI-TOF/MS.
Results were obtained using Toppgene Suite. The distribution of identified proteins according to their (A) biological processes (B) molecular functions and (C) cellular functions.
Figure 4Magnified comparison maps of spot (A) 25, (B) spot 8 and 9 in the 2-DE patterns of control and HAN.
Spot 25 had low expression in the control group but its expression increased in HAN. Spot 8 and 9 had high expression in the control group, but its expression decreased steadily in HAN.
Figure 5ELISA analysis of controls and high altitude natives.
ELISA confirmed that the mean plasma concentration of transthyretin (A) was significantly increased and transferrin (B) was significantly decreased as compared to sea level controls (p<0.01). Data represents the Mean ± SD of three independent experiments. ‘*’ showed p<0.01 when compared to controls.
Figure 6Western blot analysis of transthyretin and transferrin from plasma of controls and high altitude natives.
(A) Blots of transthyretin and transferrin were represented along with (B) their respective relative optical densities (ROD). Data represents the Mean ± SD of three independent experiments. Densitometry analysis of results from western blot, indicating significant change between the two groups compared by Student’s t-test. ‘*’ showed significantly different (p<0.05) when compared to controls.